RxDoctor Payments Data

Monther El Bzour, MD

Cardiovascular Disease · Dixon, ILNPI 1912978222

Payments from drug & device makers

$4,019in general payments, 2019–2025

Across 213 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$645
  • E.r. Squibb & Sons, L.L.C.$597
  • AstraZeneca$478
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$318
  • Boehringer Ingelheim$288
  • Johnson & Johnson$277
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,019 in reported general payments places this provider in the 60th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$349,145
Medicare patients
1,506
Services billed
5,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,043$885,443
FarxigaDapagliflozin Propanediol229$167,388
XareltoRivaroxaban216$159,117
JardianceEmpagliflozin217$156,644
Repatha SureclickEvolocumab137$115,685
EntrestoSacubitril/Valsartan110$98,013
BrilintaTicagrelor74$50,275
MultaqDronedarone Hcl35$47,835
VascepaIcosapent Ethyl80$36,083
Praluent PenAlirocumab46$28,498
Repatha SyringeEvolocumab15$16,656
NexlizetBempedoic Acid/Ezetimibe37$15,574
Atorvastatin Calcium2,037$15,168
Metoprolol Succinate1,511$14,313
ClopidogrelClopidogrel Bisulfate1,275$11,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$252$885,4431,043 claims
AstraZenecaFarxiga, Brilinta$478$217,663303 claims
Johnson & JohnsonXarelto$277$159,117216 claims
Boehringer IngelheimJardiance$288$156,644217 claims
NovartisEntresto$645$98,013110 claims
Esperion Therapeutics, Inc.Nexlizet$104$15,57437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Dixon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →